BIO

BIO

USD

Bio-Rad Laboratories Inc. Class A Common Stock

$310.960+1.090 (0.352%)

السعر في الوقت الحقيقي

Healthcare
الأجهزة الطبية
الولايات المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$309.870

الأعلى

$316.200

الأدنى

$301.920

الحجم

0.18M

أساسيات الشركة

القيمة السوقية

8.3B

الصناعة

الأجهزة الطبية

البلد

United States

إحصاءات التداول

متوسط الحجم

0.24M

البورصة

NYQ

العملة

USD

نطاق 52 أسبوعاً

الأدنى $211.43الحالي $310.960الأعلى $387.99

تقرير تحليل الذكاء الاصطناعي

آخر تحديث: ١ نوفمبر ٢٠٢٥
تم إنشاؤه بواسطة الذكاء الاصطناعيمصدر البيانات: Yahoo Finance, Bloomberg, SEC

BIO Stock Alert: Bio-Rad Laboratories Shows Short-Term Opportunity Amid Volatility

Breaking Down the Current Picture

Bio-Rad Laboratories (BIO) just wrapped up a wild October. The stock surged from $280 to $340 in three weeks, then crashed 6% in a single day after earnings. Today it’s sitting at $319.55--down from its October peak but still 5% above where it started the month. Let’s cut through the noise.

What the News Tells Us

  • Analyst split is real: Citigroup doubled down with a $375 target (22% upside), while Wells Fargo stayed cautious at $340 despite raising their forecast.
  • Earnings disappointment: The October 29 report triggered immediate selling. No details were provided in the data, but the timing aligns with BIO’s sharp 6% drop that day.
  • Sentiment is neutral overall--bullish upgrades are fighting against weak fundamentals.

Price Action Decoded

Here’s what the chart whispers:

  • The $340 wall matters: BIO tested this level twice in late October (Oct 21 and 24) but couldn’t break through. Each time, heavy selling followed.
  • Support at $318.50 is make-or-break: Yesterday’s close ($319.55) barely held above this technical floor. Volume spiked to 510K shares on the drop (Oct 29)--more than double its average.
  • That "bullish" MACD crossover? It happened at $322 on Oct 15, but the stock stalled anyway. Technicals alone won’t drive this move.

Where It’s Headed Next

Short-term signals are messy: ✅ Bullish spark: Current price hovering at the Bollinger Band lower limit ($318.51) often triggers bounces. ⚠️ Red flags: Negative ROE (-9.5%) and sky-high debt (20.7 D/E ratio) scream "fundamental trouble." 🔮 AI’s mixed forecast: +0.5% tomorrow → -0.3% the next day → +0.9% on day 3. Translation: Choppy trading ahead.

Actionable Guidance

For traders only--this isn’t a long-term hold.

Entry Strategy

  • Best window: $317-$319.50 (yesterday’s low was $315.10--don’t chase below that).
  • Why now?: Extreme volume on the drop (510K shares) suggests panic selling washed out.
  • Critical trigger: Wait for a 15-minute candle closing above $322 to confirm reversal.

Exit Plan

  • Take profit: $342 (Wells Fargo’s target). Anything beyond $345 faces serious resistance.
  • Stop loss: $314.50 (1.5% below yesterday’s low). Do not move this lower.
  • Time limit: Max 10 trading days. This setup dies if the $318 support breaks.

Who Should Skip This

  • Long-term investors: Debt and negative ROE are structural issues.
  • Risk-averse traders: The 6% single-day swing shows BIO isn’t for the faint of heart.
  • Anyone needing stability: This stock moves on earnings whispers and analyst notes--not steady growth.

Bottom Line

BIO is a short-term scalp, not a portfolio cornerstone. The $318 support level is the fulcrum. If it holds with volume

أخبار ذات صلة

Analyst Upgrades

Citigroup Maintains Buy on Bio-Rad Laboratories, Raises Price Target to $375

Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories with a Buy and raises the price target from $350 to $375.

عرض المزيد
Citigroup Maintains Buy on Bio-Rad Laboratories, Raises Price Target to $375
Analyst Upgrades

Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $340

Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories with a Equal-Weight and raises the price target from $265 to $340.

عرض المزيد
Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $340
BusinessWire

Bio-Rad Reports Third-Quarter 2025 Financial Results

Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2025. "During the third

عرض المزيد
Bio-Rad Reports Third-Quarter 2025 Financial Results

تنبؤ الذكاء الاصطناعيBeta

توصية الذكاء الاصطناعي

صعودي

تم التحديث في: ٥ نوفمبر ٢٠٢٥، ٠٣:٢٧ ص

هبوطيمحايدصعودي

66.2% الثقة

المخاطر والتداول

مستوى المخاطرة3/5
مخاطرة متوسطة
مناسب لـ
معتدل
دليل التداول

نقطة الدخول

$308.48

جني الأرباح

$317.74

وقف الخسارة

$280.36

العوامل الرئيسية

مؤشر PDI 11.1 فوق مؤشر MDI 10.1 مع مؤشر ADX 16.5، مما يشير إلى اتجاه صعودي
السعر الحالي قريب جدًا من مستوى الدعم (309.58 دولار)، مما يشير إلى فرصة شراء قوية
حجم التداول 5.4 ضعف المتوسط (3,528)، مما يشير إلى ضغط شراء قوي للغاية
مؤشر MACD -0.0968 فوق خط الإشارة -0.3920، مما يشير إلى تقاطع صعودي

ابق على اطلاع

تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.